Developing better treatments in hepatocellular carcinoma
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2010)
期刊
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
卷 4, 期 5, 页码 551-560出版社
TAYLOR & FRANCIS LTD
关键词
资金
- NIH, National Cancer Institute, Center for Cancer Research
作者
我是这篇论文的作者
推荐
Sorafenib-Loaded Cu2-xSe Nanoparticles Boost Photothermal-Synergistic Targeted Therapy against Hepatocellular Carcinoma
An-Tian Huang, Jun Du, Zhi-Yong Liu, Guang-Cong Zhang, Weinire Abuduwaili, Jia-Yan Yan, Jia-Lei Sun, Ru-Chen Xu, Tao-Tao Liu, Xi-Zhong Shen, Ling Dong, Ji-Min Zhu, Yuhao Li
NANOMATERIALS (2022)
Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study
Shou-Sheng Chu, Yu-Hsuan Kuo, Wen-Shan Liu, Shih-Chang Wang, Chung-Han Ho, Yi-Chen Chen, Ching-Chieh Yang, Hung-Chang Wu
SCIENTIFIC REPORTS (2021)
Bimodal Treatment of Hepatocellular Carcinoma by Targeted Minimally Interventional Photodynamic/Chemotherapy Using Glyco-Covalent-Organic Frameworks-Guided Porphyrin/Sorafenib
Jun Hu, Jing Hu, Wenrui Wu, Yufei Qin, Junjie Fu, Chao Liu, Peter H. Seeberger, Jian Yin
ACTA BIOMATERIALIA (2022)
Sorafenib Plus Hepatic ArterialInfusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized TriaL
Kanglian Zheng, Xu Zhu, Shijie Fu, Guang Cao, Wen-Qing Li, Liang Xu, Hui Chen, Di Wu, Renjie Yang, Kun Wang, Wei Liu, Hongwei Wang, Quan Bao, Ming Liu, Chunyi Hao, Lin Shen, Baocai Xing, Xiaodong Wang
RADIOLOGY (2022)
Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study
Bowen Chen, Linzhi Zhang, Jiamin Cheng, Tong Wu, Jin Lei, Xu Yang, Rongling Zhang, Rifaat Safadi, Yinyin Li, Tongguo Si, Yinying Lu
DRUG DESIGN DEVELOPMENT AND THERAPY (2022)
Matrix stiffness-dependent STEAP3 coordinated with PD-L2 identify tumor responding to sorafenib treatment in hepatocellular carcinoma
Shunxi Wang, Long Chen, Wanqian Liu
CANCER CELL INTERNATIONAL (2022)
Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
Yuan-Hung Kuo, Yi-Hao Yen, Yen-Yang Chen, Kwong-Ming Kee, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Jing-Houng Wang
FRONTIERS IN ONCOLOGY (2021)
Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo
Mahmoud A. Younis, Ikramy A. Khalil, Yaser H. A. Elewa, Yasuhiro Kon, Hideyoshi Harashima
JOURNAL OF CONTROLLED RELEASE (2021)
Potential Treatment Strategies for Hepatocellular Carcinoma Cell Sensitization to Sorafenib
Zhonghao Jiang, Chaoliu Dai
JOURNAL OF HEPATOCELLULAR CARCINOMA (2023)
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Thomas Yau, Joong-Won Park, Richard S. Finn, Ann-Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, James J. Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, Eckart Schott, Su Pin Choo, Robin Kate Kelley, Wolfgang Sieghart, Eric Assenat, Renata Zaucha, Junji Furuse, Ghassan K. Abou-Alfa, Anthony B. El-Khoueiry, Ignacio Melero, Damir Begic, Gong Chen, Jaclyn Neely, Tami Wisniewski, Marina Tschaika, Bruno Sangro
LANCET ONCOLOGY (2022)
H-TEX-mediated signaling between hepatocellular carcinoma cells and macrophages and exosome-targeted therapy for hepatocellular carcinoma
Sihang Yu, Lei Zhou, Jiaying Fu, Long Xu, Buhan Liu, Yuanxin Zhao, Jian Wang, Xiaoyu Yan, Jing Su
FRONTIERS IN IMMUNOLOGY (2022)
Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
Dae-Won Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae-Yong Kim, Sae-Won Han, Youn Oh, Seock-Ah Im, Tae-You Kim, Youngeun Lee, Haeryoung Kim, Kyung-Hun Lee
CLINICAL CANCER RESEARCH (2021)
Iridium Complex-Loaded Sorafenib Nanocomposites for Synergistic Chemo-photodynamic Therapy of Hepatocellular Carcinoma
Weinire Abuduwaili, Xiang Wang, An-Tian Huang, Jia-Lei Sun, Ru-Chen Xu, Guang-Cong Zhang, Zhi-Yong Liu, Fu Wang, Chang-Feng Zhu, Tao-Tao Liu, Ling Dong, Ji-Min Zhu, Shu-Qiang Weng, Yuhao Li, Xi-Zhong Shen
ACS APPLIED MATERIALS & INTERFACES (2022)
Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma
Mukesh Kumar, Ramanpreet Kaur, Shruthi Kanthaje, Radha K. K. Dhiman, Anuradha Chakraborti
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)
Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma
Jialiang Luo, Lei Li, Zhengyumeng Zhu, Bo Chang, Fan Deng, Di Wang, Xiao Lu, Daming Zuo, Qingyun Chen, Jia Zhou
BIOMEDICINE & PHARMACOTHERAPY (2022)
'Invisible' immune checkpoint molecule causing resistance to anti-PD1 therapy in HCC
Tim F. Greten
GUT (2023)
Immunology and immunotherapy of cholangiocarcinoma
Tim F. Greten, Robert Schwabe, Nabeel Bardeesy, Lichun Ma, Lipika Goyal, Robin K. Kelley, Xin W. Wang
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2023)
The Microbiome and Liver Cancer
Yuta Myojin, Tim F. Greten
CANCER JOURNAL (2023)
Medication effects on the gut microbiome in allo-HCT
Welles Robinson, Michael Gertz, Tim F. Greten, Eytan Ruppin
CELL (2023)
Purine anabolism creates therapeutic vulnerability in hepatocellular carcinoma through m6A-mediated epitranscriptomic regulation
Man Hsin Hung, Ching Wen Chang, Kathy Cheng Wang, Jittiporn Chaisaingmongkol, Mathuros Ruchirawat, Tim F. Greten, Xin Wei Wang
HEPATOLOGY (2023)
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer
Cecilia Monge, Changqing Xie, Yuta Myojin, Kelley Coffman, Donna Mabry Hrones, Sophie Wang, Jonathan M. Hernandez, Bradford J. Wood, Elliot B. Levy, Israa Juburi, Stephen M. Hewitt, David E. Kleiner, Seth M. Steinberg, William D. Figg, Bernadette Redd, Philip Homan, Maggie Cam, Benjamin Ruf, Austin G. Duffy, Tim F. Greten
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)
Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy
Anuradha Budhu, Erica C. Pehrsson, Aiwu He, Lipika Goyal, Robin Kate Kelley, Hien Dang, Changqing Xie, Cecilia Monge, Mayank Tandon, Lichun Ma, Mahler Revsine, Laura Kuhlman, Karen Zhang, Islam Baiev, Ryan Lamm, Keyur Patel, David E. Kleiner, Stephen M. Hewitt, Bao Tran, Jyoti Shetty, Xiaolin Wu, Yongmei Zhao, Tsai-Wei Shen, Sulbha Choudhari, Yuliya Kriga, Kris Ylaya, Andrew C. Warner, Elijah F. Edmondson, Marshonna Forgues, Tim F. Greten, Xin Wei Wang
CELL REPORTS MEDICINE (2023)
The current landscape of therapies for hepatocellular carcinoma
Kelley Coffman-D'Annibale, Changqing Xie, Donna M. Hrones, Shadin Ghabra, Tim F. Greten, Cecilia Monge
CARCINOGENESIS (2023)
Biomarkers for immunotherapy of hepatocellular carcinoma
Tim F. Greten, Augusto Villanueva, Firouzeh Korangy, Benjamin Ruf, Mark Yarchoan, Lichun Ma, Eytan Ruppin, Xin W. Wang
NATURE REVIEWS CLINICAL ONCOLOGY (2023)
Hispanic Individuals are Underrepresented in Phase III Clinical Trials for Advanced Liver Cancer in the United States
Cecilia Monge, J. Alberto Maldonado, Katherine A. McGlynn, Tim F. Greten
JOURNAL OF HEPATOCELLULAR CARCINOMA (2023)
Disparities in multinational phase III liver cancer clinical trials by regions of the world
J. Alberto Maldonado, Katherine A. McGlynn, Tim F. Greten, Cecilia Monge
CANCER RESEARCH (2023)
Racial and ethnic disparities in US clinical trials in liver cancer in the last nineteen years
J. Alberto Maldonado, Barry I. Graubard, Katherine A. McGlynn, Tim F. Greten, Cecilia Monge
CANCER RESEARCH (2023)
CSF-1R+macrophages control the gut microbiome-enhanced liver NKT function through IL-18
Chi Ma, Justin McCallen, John C. McVey, Qianfei Zhang, Benjamin Ruf, Kylynda Bauer, Sophie Wang, Chunwei Walter Lai, Giorgio Trinchieri, Jay A. Berzofsky, Firouzeh Korangy, Tim F. Greten
CANCER RESEARCH (2023)
Activation of purine anabolism creates a therapeutic vulnerability in hepatocellular carcinoma via m6A-mediated epitranscriptomic regulation
Man-Hsin Hung, Ching Wen Chang, Kathy Cheng Wang, Jittiporn Chaisaingmongkol, Mathuros Ruchirawat, Tim F. Greten, Xin Wei Wang
CANCER RESEARCH (2023)
Innate lymphoid cells and innate-like T cells in cancer - at the crossroads of innate and adaptive immunity
Benjamin Ruf, Tim F. Greten, Firouzeh Korangy
NATURE REVIEWS CANCER (2023)